接受 CAR-T 细胞治疗的老年患者的临床结局与毒性

Chimeric antigen receptor T cell therapy (CAR-T) has transformed the treatment landscape for adults with relapsed/refractory hematologic malignancies, but few studies have examined outcomes in older adults.

We aimed to evaluate clinical outcomes and treatment toxicity in older adults receiving CAR-T for hematologic malignancies and to describe outcomes and toxicities in older adults age 75+ years compared to those age 65 to 74 years.

We conducted a retrospective analysis of 141 adult patients age 65+ years (46. 1% age 75+ years) who received commercial CAR-T at Massachusetts General Hospital between December 2017 and June 2023.

We abstracted clinical outcomes from a review of the electronic health record, including (1) toxicity (ie, cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS]); (2) health care utilization; (3) overall survival (OS); and (4) event-free survival (EFS).

We analyzed the association of age (65 to 74 years versus 75+ years) with toxicity and health care utilization using the Mann-Whitney U test for continuous variables and the Fisher exact test for categorical variables.

We examined the association of age with OS and EFS using multivariable Cox regression, controlling for covariates. The median patient age was 77 years (range, 75 to 91 years) in the 75+ year group and 69 years (ranges, 65 to 74 years) in the 65 to 74 year group. There were no statistically significant differences between the 75+ year group and the 65 to 74 year group in the rates of CRS (75. 4% versus 84. 2%; P = . 21), grade 3+ CRS (1. 5% versus 6. 6%; P = . 24), ICANS (38. 5% versus 48. 7%; P = . 24), grade 3+ ICANS (16. 9% versus 21. 1%; P = . 49), or infections (23. 1% versus 29. 0%; P = . 45).

There were no significant between-group differences in hospital readmissions within 30 days of CAR-T (10. 8% versus 21. 1%; P = . 11), intensive care unit admissions within 30 days of CAR-T (7. 7% versus 9. 2%; P = 1. 000), or median hospital length of stay (13 days versus 14 days; P = . 29) among age groups.

In a multivariable Cox regression analysis controlling for CAR-T product, Eastern Cooperative Oncology Group Performance Status, lactate dehydrogenase level, bridging therapy use, and history of deep venous thromboembolism, age 75+ years was not associated with OS (hazard ratio [HR], . 95; P = . 86) or EFS (HR, 1. 28; P = . 30).

We identified favorable OS and toxicity outcomes across age categories in older adults receiving CAR-T for B cell non-Hodgkin lymphoma or multiple myeloma, underscoring that age alone is not a contraindication for CAR-T.